advertisement
Abstract #45976 Published in IGR 13-2
Efficiency of glaucoma drug regulation in 5 European countries: A 1995-2006 longitudinal prescription analysis
De Natale R; Le Pen C; Berdeaux GJournal of Glaucoma 2011; 20: 234-239
Purpose: To compare the evolution of prostaglandin analog (PGA) and (beta)-blocker (BB) prescriptions across 5 European countries. Methods: Data were extracted from various SOURCEs: (1) IMS data for France, Germany, Italy, Spain, and the United Kingdom, (2) glaucoma-treated patients from the United Kingdom General Practice Research Database (UK-GPRD), (3) prescriptions delivered by the territorial pharmaceutical service of Monselice of the Padova region (Italy). Drugs were grouped into 3 classes: PGAs, BBs, and other drugs. Yearly market shares were calculated. Treatment persistence survival curves were estimated for Italian and UK data, and the 3 drug groups were compared using the Cochran Mantel Haenszel test. Results: According to Padova data, BBs decreased in market share, whereas PGAs increased. A linear extrapolation of these market shares, based on 1998 to 2003 data, predicted that the 2 curves should cross in 2005, a prediction reinforced by the European Medicines Agency authorization (2002) of PGAs as first-line glaucoma treatments. That this did not occur may be explained by Italy's refusal to reimburse PGAs as first-line therapy. IMS data identified Italy and Germany as 2 countries in which BBs are still more frequently prescribed than PGAs. Treatment persistence with PGAs as monotherapy, in PGA-naive patients, was longer than for BBs according to both Padova and UK-GPRD data. This held true for both first-line and second-line PGA prescriptions (UK-GPRD); the persistence of second-line PGA equalled first-line BB treatment. Conclusion: Health care regulations impacted upon glaucoma prescribing and may be one of the reasons for different annual evolution rates of PGA and BB prescriptions
G. Berdeaux. Alcon France, 4, Rue Henri Sainte-Claire Deville, F-92563 Rueil-Malmaison Cedex, France. Email: gilles.berdeaux@alconlabs.com
Classification:
15 Miscellaneous
14 Costing studies; pharmacoeconomics
11.4 Prostaglandins (Part of: 11 Medical treatment)
11.3.4 Betablocker (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
